Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | OSBP | P22059 | 2/20 | 0.55 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.55 |
| ▸ | RORC | P51449 | 1/20 | 0.55 |
| ▸ | GPR183 | P32249 | 2/20 | 0.50 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.49 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.49 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863638 | 0.90 | USP2 (0.74) | LMNANPC1L1USP2OSBPRORC | |
| SCHEMBL29015206 | 0.90 | USP2 (0.74) | LMNANPC1L1USP2OSBPRORC | |
| SCHEMBL14924215 | 0.90 | USP2 (0.74) | LMNANPC1L1USP2OSBPRORC | |
| SCHEMBL13076840 | 0.87 | NPC1L1 (0.83) | LMNANPC1L1USP2OSBPNR1H3 | |
| SCHEMBL7990443 | 0.87 | LMNA (0.58) | LMNANPC1L1USP2OSBPNR1H3 | |
| SCHEMBL27730341 | 0.87 | LMNA (0.56) | LMNANPC1L1USP2GPBAR1AKR1B10 | |
| SCHEMBL1517837 | 0.87 | LMNA (0.56) | LMNANPC1L1USP2GPBAR1AKR1B10 | |
| SCHEMBL26653759 | 0.85 | NPC1L1 (0.60) | LMNANPC1L1USP2OSBPNR1H3 | |
| SCHEMBL28271545 | 0.85 | NPC1L1 (0.57) | LMNANPC1L1USP2GPBAR1AKR1B10 | |
| SCHEMBL29289385 | 0.85 | GPBAR1 (0.69) | LMNANPC1L1USP2GPBAR1AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 927 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062716-A1 | LIPID NANOPARTICLE (LNP) COMPOSITION OR FORMULATION FOR NUCLEIC ACID THERAPEUTICS | POPVAX PRIVATE LTD (IN) | 2026-03-05 | — | — | US | claimed |
| EP-4577196-A1 | LIPID NANOPARTICLE (LNP) COMPOSITION OR FORMULATION FOR NUCLEIC ACID THERAPEUTICS | Popvax Private Limited (IN) | 2025-07-02 | — | — | EP | claimed |
| WO-2025052180-A2 | LIPIDS AND LIPID NANOPARTICLES | Axelyf ehf. (IS) | 2025-03-13 | — | — | WO | claimed |
| WO-2024044178-A1 | LIPID NANOPARTICLE (LNP) COMPOSITION OR FORMULATION FOR NUCLEIC ACID THERAPEUTICS | POPVAX PRIVATE LIMITED (IN) | 2024-02-29 | — | — | WO | claimed |
| EP-3368024-B1 | COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | AKOS BIOSCIENCES INC (US) | 2023-09-20 | — | — | EP | claimed |
| US-20220054429-A1 | COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | AKOS BIOSCIENCES, INC. | 2022-02-24 | — | — | US | claimed |
| EP-2411052-B1 | CARRIER COMPRISING A VITAMIN E DERIVATIVE AND ANNEXIN V | UCL BUSINESS LTD (GB) | 2020-10-07 | — | — | EP | claimed |
| US-20180311182-A1 | COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | AKOS BIOSCIENCES, INC. | 2018-11-01 | — | — | US | claimed |
| EP-3368024-A1 | COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | Jay Pharma, Inc. (CA) | 2018-09-05 | — | — | EP | claimed |
| WO-2017072773-A1 | COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | NATHAN ILANA (IL) | 2017-05-04 | — | — | WO | claimed |
| US-9580711-B2 | Lipid particles with asymmetric cationic lipids for RNA delivery | ARCTURUS THERAPEUTICS, INC. (US) | 2017-02-28 | — | — | US | claimed |
| US-9545392-B2 | Carrier comprising a vitamin E derivative | UCL BUSINESS PLC (GB) | 2017-01-17 | — | — | US | claimed |
| US-20160244761-A1 | LIPID PARTICLES WITH ASYMMETRIC CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2016-08-25 | — | — | US | claimed |
| US-20120115771-A1 | CARRIER | UCL BUSINESS PLC (GB) | 2012-05-10 | — | — | US | claimed |
| EP-2411052-A2 | CARRIER COMPRISING A VITAMIN E DERIVATIVE | UCL Business PLC (GB) | 2012-02-01 | — | — | EP | claimed |
| WO-2010109212-A2 | CARRIER | UCL BUSINESS PLC (GB) | 2010-09-30 | — | — | WO | claimed |
| US-12637422-B2 | Ionizable cationic lipid for RNA delivery | ARCTURUS THERAPEUTICS, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2026102141-A1 | COMPOSITIONS FOR PCSK9 GENE EDITING AND METHODS OF USING SAME FOR TREATMENT OF DISEASE | VERVE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062716-A1 | LIPID NANOPARTICLE (LNP) COMPOSITION OR FORMULATION FOR NUCLEIC ACID THERAPEUTICS | CETP, PLTP, LDLR | LMNA 123/4885NPC1L1 5/4885USP2 3448/4885 |
| US-12637422-B2 | Ionizable cationic lipid for RNA delivery | POLRMT, SLC27A1, SLC43A1 | LMNA 287/4885NPC1L1 6/4885USP2 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.